A tunable dual-promoter integrator for targeting of cancer cells
暂无分享,去创建一个
[1] J. Thevelein,et al. Budding yeast as a screening tool for discovery of nucleoside analogs for use in HSV-1 TK suicide-gene therapy. , 1999, BioTechniques.
[2] S. Semple-Rowland,et al. Targeted expression of two proteins in neural retina using self-inactivating, insulated lentiviral vectors carrying two internal independent promoters. , 2007, Molecular vision.
[3] Farren J. Isaacs,et al. Tracking, tuning, and terminating microbial physiology using synthetic riboregulators , 2010, Proceedings of the National Academy of Sciences.
[4] M. Fussenegger,et al. Advanced modular self-inactivating lentiviral expression vectors for multigene interventions in mammalian cells and in vivo transduction. , 2002, Nucleic acids research.
[5] L. Nissim,et al. An autonomous system for identifying and governing a cell's state in yeast , 2007, Physical biology.
[6] J. Hopfield. Kinetic proofreading: a new mechanism for reducing errors in biosynthetic processes requiring high specificity. , 1974, Proceedings of the National Academy of Sciences of the United States of America.
[7] S. Andreadis,et al. Independent and high-level dual-gene expression in adult stem-progenitor cells from a single lentiviral vector , 2009, Gene Therapy.
[8] A. Hoffmann,et al. Transcriptional regulation via the NF-kappaB signaling module. , 2006, Oncogene.
[9] Eytan Domany,et al. The promoters of human cell cycle genes integrate signals from two tumor suppressive pathways during cellular transformation , 2005, Molecular systems biology.
[10] R. Strieter,et al. CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer , 2006, The Journal of experimental medicine.
[11] E. Rogakou,et al. DNA Double-stranded Breaks Induce Histone H2AX Phosphorylation on Serine 139* , 1998, The Journal of Biological Chemistry.
[12] W. Ramsey,et al. The bystander effect in the HSVtk/ganciclovir system and its relationship to gap junctional communication , 1998, Gene Therapy.
[13] J. Yee,et al. Gene expression from transcriptionally disabled retroviral vectors. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[14] J. Chen,et al. Tightly-regulated suicide gene expression kills PSA-expressing prostate tumor cells , 2005, Gene Therapy.
[15] R. Müller,et al. A synthetic leucine zipper-based dimerization system for combining multiple promoter specificities , 2001, Gene Therapy.
[16] E. Small,et al. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[17] X. Zhan,et al. Lentiviral vectors with two independent internal promoters transfer high-level expression of multiple transgenes to human hematopoietic stem-progenitor cells. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.
[18] Ying Huang,et al. Antitumor efficacy and tumor-selective replication with a single intravenous injection of OAS403, an oncolytic adenovirus dependent on two prevalent alterations in human cancer , 2004, Cancer Gene Therapy.
[19] V. Rotter,et al. Prolonged culture of telomerase-immortalized human fibroblasts leads to a premalignant phenotype. , 2003, Cancer research.
[20] D. Yee,et al. Inducible expression of herpes simplex virus thymidine kinase increases sensitivity to ganciclovir but does not enhance bystander effect in breast cancer cells , 2000, Breast Cancer Research and Treatment.
[21] F. Guerlesquin,et al. Protein–protein interaction inhibition (2P2I) combining high throughput and virtual screening: Application to the HIV-1 Nef protein , 2007, Proceedings of the National Academy of Sciences.
[22] Christopher A. Voigt,et al. Environmental signal integration by a modular AND gate , 2007, Molecular systems biology.
[23] V. Rotter,et al. Transcriptional programs following genetic alterations in p53, INK4A, and H-Ras genes along defined stages of malignant transformation. , 2005, Cancer research.
[24] Y. Tesfaigzi,et al. How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer? , 2009, Cell cycle.
[25] O. Gofrit,et al. Regulatory sequences of the H19 gene in DNA based therapy of bladder cancer , 2004 .
[26] James J. Collins,et al. A Tunable Genetic Switch Based on RNAi and Repressor Proteins for Regulating Gene Expression in Mammalian Cells , 2007, Cell.
[27] M Schwab,et al. N‐myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis , 2001, The EMBO journal.
[28] S. Kain,et al. Generation of Destabilized Green Fluorescent Protein as a Transcription Reporter* , 1998, The Journal of Biological Chemistry.
[29] Wendell A. Lim,et al. Designing customized cell signalling circuits , 2010, Nature Reviews Molecular Cell Biology.
[30] Özlem Türeci,et al. SSX: A multigene family with several members transcribed in normal testis and human cancer , 1997, International journal of cancer.
[31] Ian M Thompson,et al. Prostate‐specific antigen: A review of the validation of the most commonly used cancer biomarker , 2004, Cancer.
[32] Zhen Xie,et al. Rationally-designed logic integration of regulatory signals in mammalian cells , 2010, Nature nanotechnology.
[33] J. Nör,et al. Transcriptional targeting of tumor endothelial cells for gene therapy. , 2009, Advanced drug delivery reviews.
[34] P. Kantoff,et al. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[35] Kevin C. Chen,et al. A transgenic mouse model with a luciferase reporter for studying in vivo transcriptional regulation of the human CYP3A4 gene. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[36] Fred H. Gage,et al. Development of a Self-Inactivating Lentivirus Vector , 1998, Journal of Virology.
[37] I. Stratford,et al. Targeting gene therapy to cancer: a review. , 1997, Oncology research.
[38] M. Ptashne. How eukaryotic transcriptional activators work , 1988, Nature.
[39] A. Abbruzzese,et al. Modulation of molecular mechanisms involved in protein synthesis machinery as a new tool for the control of cell proliferation. , 2000, European journal of biochemistry.
[40] R. Müller,et al. Tissue-specific, cell cycle-regulated chimeric transcription factors for the targeting of gene expression to tumor cells. , 1998, Human gene therapy.
[41] A. Hoffmann,et al. Transcriptional regulation via the NF-κB signaling module , 2006, Oncogene.
[42] E. Bayer,et al. Functional asymmetry in cohesin binding belies inherent symmetry of the dockerin module: insight into cellulosome assembly revealed by systematic mutagenesis. , 2008, The Biochemical journal.
[43] R. Naviaux,et al. The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses , 1996, Journal of virology.
[44] G. Evan,et al. c‐Myc‐induced apoptosis in fibroblasts is inhibited by specific cytokines. , 1994, The EMBO journal.
[45] R. Warnick,et al. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. , 1993, Human gene therapy.
[46] E. Bayer,et al. Matching fusion protein systems for affinity analysis of two interacting families of proteins: the cohesin–dockerin interaction , 2005, Journal of molecular recognition : JMR.
[47] E. Mekada,et al. One molecule of diphtheria toxin fragment a introduced into a cell can kill the cell , 1978, Cell.
[48] D. Nettelbeck,et al. Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis. , 2009, Advanced drug delivery reviews.
[49] D. Nettelbeck. Cellular genetic tools to control oncolytic adenoviruses for virotherapy of cancer , 2008, Journal of Molecular Medicine.
[50] Martin Fussenegger,et al. Recent advances in mammalian synthetic biology-design of synthetic transgene control networks. , 2009, Current opinion in biotechnology.
[51] V. Rotter,et al. p53 Regulates the Ras circuit to inhibit the expression of a cancer-related gene signature by various molecular pathways. , 2010, Cancer research.
[52] G. Evan,et al. A matter of life and cell death. , 1998, Science.
[53] P. Nilsson,et al. Hypoxia induces p53-dependent transactivation and Fas/CD95-dependent apoptosis , 2007, Cell Death and Differentiation.
[54] C. Heldin,et al. Dimerization of cell surface receptors in signal transduction , 1995, Cell.
[55] D O Morgan,et al. Cyclin-dependent kinases: engines, clocks, and microprocessors. , 1997, Annual review of cell and developmental biology.
[56] S. Thorne,et al. Dual Promoter–Controlled Oncolytic Adenovirus CG5757 Has Strong Tumor Selectivity and Significant Antitumor Efficacy in Preclinical Models , 2005, Clinical Cancer Research.